Skip to main content
DeutschDE
European Commission logo print header

Implant Disposable Antibacterial Coating (I.D.A.C.): a Novel Approach to Implant-Related Infections in Orthopaedics and Trauma Surgery

Ziel

With a share of 38%, orthopaedic and traumatology (O&T) are the worldwide leading markets of implanted biomaterials, involving millions of new patients each year at an increasing trend. Infection related to implanted medical devices is directly related to bacterial capability to establish multilayered, highly structured biofilms on artificial surfaces. Bacterial infections due to implanted biomaterials represent the most devastating complication in O&T, involving millions of European citizens. Aim of the present research is to develop, validate and bring to the market a disposable coating of implanted biomaterial (Implant Disposable Antibacterial Coating, I.D.A.C.). The device, based on a novel, proprietary, resorbable hydrogel, would act as a fast resorbable local delivery carrier of antibiofilm and antibacterial compounds. The active drug (antibiofilm and antibiotic agents) will be mixed at the time of the hydrogel application, allowing the correct choice for any given patient, reducing regulatory requirements, improving storage life and versatility. In particular, I.D.A.C. will be tested as a resorbable carrier of drugs (e.g.: N-acetylcisteine and its derivatives, serratia peptidase and other peptides, etc.) already known from our studies for having excellent antibiofilm properties, while others are able to by-pass the intact biofilm barrier and kill the underlying bacteria, when locally administered. The final purpose of the present research is to set a novel approach to early control of biofilm formation,to prevent bacterial colonization of implanted material and to treat established implant-related infections and chronic wounds, without any risk of inducing new drug resistance and alter the environment. The research will be conducted under the aegis of the European Bone and Joint Infection Society and the European Hip Society, through a network of upper standard European research and clinical centers and experienced SMEs from eight Countries around Europe.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2011-two-stage
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

NOVAGENIT SRL
EU-Beitrag
€ 658 138,00
Adresse
VIALE TRENTO 115/117
38017 MEZZOLOMBARDO
Italien

Auf der Karte ansehen
Region
Nord-Est Provincia Autonoma di Trento Trento
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten

Beteiligte (11)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 9 Januar 2017

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/277988/de

European Union, 2024